Science & Platform

Boosting T cell responses directly in the tumor microenvironment

T cells need two signals: tumor targeting as the ignition and costimulation as boost. TWYCE delivers the boost where it is missing: in the tumor microenvironment.

Our science starts where existing immuno-oncology therapies fall short.

Overcoming the limitations of cancer immunotherapy

Immunotherapy has transformed cancer treatment, yet durable responses in solid tumors remain challenging. Limited tumor specificity, off-tumor toxicity and an immunosuppressive tumor microenvironment continue to restrict efficacy and dosing.

TWYCE enables the next level of T cell activation.

Effective T cell responses require two signals: tumor recognition via the T cell receptor (TCR/CD3) and a second, costimulatory signal. While tumors can trigger the first, the second is often missing or insufficient.

TWYCE brings both signals together, directing costimulation to the tumor microenvironment to drive a more specific and sustained anti-tumor immune response.

Our BiCo platform is built around three principles:

Full-blown T cell activity

Combining tumor targeting with TME-anchored CD28 costimulation for a powerful, sustained T cell response.

Specificity

Targeting tumor-associated antigen combinations that are not co-expressed on healthy tissue.

Multiplexed TME platform

One costimulatory backbone can be paired with different tumor-targeting approaches, supporting both TWYCE and partner programs.

Two sites. One coordinated anti-tumor immune response.

A full T cell response requires two coordinated signals. TWYCE brings them together across distinct sites in the TME, combining tumor targeting with locally anchored costimulation where immune activation is otherwise suppressed.

Signal 1: a TWYCE TCE (CC) binds TAA1 on a tumor cell and CD3 on a T cell, triggering cytokine release

Signal 1: Ignition

Target the tumor: a CD3 TCE, peptide vaccine or partner molecule tells T cells what to attack.

Signal 2: a BiCo binds TAA2 in the tumor microenvironment and CD28 on a T cell

Signal 2: Boost

Sustain the response: our BiCo delivers the CD28 signal at the TME, where immune activation is otherwise suppressed.

Signal 1 and Signal 2 together: a CC and a BiCo engage one T cell, which proliferates and drives tumor cell death

Signal 1 + 2: Tumor elimination

A sustained response: with both signals present, T cells expand at the tumor site and stay engaged, achieving durable tumor cell killing and long-lasting immunity.

TME-anchored CD28 costimulation can foster multiple Signal 1 approaches.

The platform of TWYCE builds upon a unique approach: two compartments, two signals. Signal 1 targets the tumor cell and directs T cells to what they should attack; Signal 2 provides CD28 costimulation at the surrounding immunosuppressive stroma. Our BiCos deliver Signal 2 by binding CD28 and a target in the TME, such as FAP in our lead program. They are paired with own CD3 TCEs and cancer vaccines, but are also available for partner-provided Signal 1 programs.

Signal 1 and Signal 2 together: a CC and a BiCo engage one T cell, which proliferates and drives tumor cell death

BiCos in combination with TCEs

Signal 1 and Signal 2 are delivered by TCEs targeting the tumor and TME-anchored BiCos. Full T cell activation occurs only when both bispecifics have bound their respective targets, which allows for largely increased specificity, reduced toxicity and sustained efficiency.

A cancer vaccine primes a T cell through TCR and MHC, while a BiCo bound in the tumor microenvironment adds CD28 costimulation, leading to tumor cell death

BiCos in combination with cancer vaccines

Cancer vaccines induce tumor-specific T cells enabling targeting of intracellular antigens; BiCos boost the T cells within the TME where they are usually suppressed, which allows for the expansion required to combat high tumor burden and sustains efficacy.

Signal 1

Ignition by tumor targeting

TWYCE T cell engager (CC)
TWYCE TCE (CC)
TWYCE cancer vaccine
TWYCE cancer vaccine
Placeholders for a partner-provided T cell engager and a partner-provided cancer vaccine
Bring your own TCE and vaccine

Signal 2

Boost by targeting TME

TWYCE TME BiCo
TWYCE TME BiCo

One BiCo, multiple combinations

Our BiCos can provide the missing Signal 2 for multiple Signal 1 approaches: partners can pair their own TCEs or vaccines with our TME-anchored BiCos to add the missing costimulation.